Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Russian Registry of Patients With Neovascular Age-Related Macular Degeneration (nAMD)

NCT04935411 is registered in ClinicalTrials.gov with Novartis Pharmaceuticals as lead sponsor.

NCT NCT04935411
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04935411 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Russian Registry of Patients With Neovascular Age-Related Macular Degeneration (nAMD)
Lead sponsor
Novartis Pharmaceuticals
Phase
Observational
Overall status
Terminated
Start date
December 20, 2020
Completion date
December 5, 2022
Enrollment
2,665 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

neovascular age-related macular degeneration